Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/10/2024 | $13.00 | Buy | UBS |
| 10/9/2024 | $16.00 | Buy | Rodman & Renshaw |
| 7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
| 3/4/2024 | $40.00 | Overweight | Morgan Stanley |
| 3/4/2024 | $39.00 | Overweight | JP Morgan |
| 3/4/2024 | $44.00 | Overweight | Wells Fargo |
| 3/4/2024 | $48.00 | Outperform | Leerink Partners |
A revolutionary cell-based gene therapy is showing promise for treating autoimmune diseases. Professor Georg Schett, a rheumatologist at University Hospital Erlangen in eastern Germany, used chimeric antigen receptor (CAR-T) cell therapy, typically used for blood cancers, for autoimmune conditions like lupus, when the immune system attacks healthy cells and tissues by mistake. This attack causes inflammation. The Financial Times writes that the early success of CAT-T therapy has reignited discussions about its potential beyond blood cancers, though challenges remain. Professor Georg Schett noted that this approach could revolutionize autoimmune disease treatment, providing a one-tim
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Kyverna Therapeutics (NASDAQ:KYTX) with a Neutral and maintains $8 price target.
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Bank of America Corporation (NYSE:BAC) to report quarterly earnings at 80 cents per share on revenue of $25.22 billion before the opening bell. Bank of America shares gained 0.1% to $41.94 in after-hours trading. FB Financial Corporation (NYSE:FBK) posted better-than-expected results for its second quarter on Monday. FB Financial shares rose 0.5% to $43.03 in the after-hours trading session. Analysts are expecting Morgan Stanley (NYSE:MS) to post quarterly earnings at $1.65 per share on revenue of $14.3 billion. The company will r
Poster #14-006 describes the first successful treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR-T cells Kyverna to host a conference call on April 16 to review recent named-patient experience in patients suffering from multiple sclerosis and myasthenia gravis EMERYVILLE, Calif., April 11, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today its attendance at the 2024 annual meeting of the American Academy of Neurology to be held in Denver, Colorado, starting
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)
UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00
Rodman & Renshaw initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $16.00
H.C. Wainwright initiated coverage of Kyverna Therapeutics with a rating of Neutral and set a new price target of $8.00
10-Q - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
Positive Sustained Efficacy and Durability at >6-month Follow-Up Observed in Patients With Severe Lupus Nephritis (LN) Treated With KYV-101 Target Dose KYV-101 Treatment Continues to Demonstrate Robust Safety and Tolerability With No High-Grade CRS or ICANS Observed EMERYVILLE, Calif., Nov. 14, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announces today that it will present updated clinical data from LN patients treated with KYV-101 in ongoing Kyverna-sponsored KYSA-1 and KYSA-3 Phase 1/2 studies and named patient treatments. Kyverna, alongside leading academi
Multiple Key Leadership Appointments, Including Warner Biddle as CEO, Bringing Clinical, Commercial and Strategic Expertise in Cell Therapy Continuing to Advance Broad KYSA Clinical Development Program: Presented Clinical Data Highlighting Potential for KYV-101 in SPS, MG and MS at ECTRIMS and Plan to Share Updated Clinical Data in LN at Company Symposium at ACR Convergence 2024 Strong Financial Position; Ended the Quarter With $321.6 Million in Cash, Cash Equivalents and Marketable Securities EMERYVILLE, Calif., Nov. 13, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy EMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors. Mr. Aktar has over two decades of biopharmaceutical experience, melding more tha
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
3 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
Enriches Board's expertise in corporate strategy and business development, with vast experience leading biopharmaceutical companies through rapid growth and creating value across innovative therapeutic platforms, including cell therapy EMERYVILLE, Calif., Oct. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of biotechnology executive and cell therapy veteran Mert Aktar as an independent director to its Board of Directors. Mr. Aktar has over two decades of biopharmaceutical experience, melding more tha
The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University The agreements further expand the scale of ongoing clinical studies assessing the potential therapeutic effects of KYV-101 in multiple diseases and locations around the world EMERYVILLE, Calif., March 7, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapie